An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• Have signed an informed consent form before participating in the research.
• Male or female individuals aged 50 or above at the time of signing the informed consent form;
• Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
• At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).
Locations
Other Locations
China
Shanghai general hospital
RECRUITING
Shanghai
Contact Information
Primary
Yating Liu
yating.liu@innoventbio.com
86 15821084695
Time Frame
Start Date: 2025-12-05
Estimated Completion Date: 2026-08-30
Participants
Target number of participants: 800
Treatments
Experimental: IBI302 8mg dose 8mg
Drug: IBI302 8mg/Intravitreal injection
Related Therapeutic Areas
Sponsors
Leads: Innovent Biologics Technology Limited (Shanghai R&D Center)